The Triple I Community of Utrecht Life Sciences is pleased to announce the launch of Tumor Immunology Seminar Series at Utrecht Science Park, bringing together researchers from across Utrecht’s immunology and oncology disciplines.
Organised in collaboration with Universiteit Utrecht, UMC Utrecht, the Hubrecht Institute, and the Prinses Máxima Centrum, the series highlights cutting-edge work in immune-oncology and translational immunotherapy.
The series takes place monthly (second Thursday, 11:00–12:00) at the Hubrecht Institute Auditorium, followed by a “Meet the Expert” lunch (registration required).
📍 Hubrecht Institute Auditorium, Utrecht
🔗 Registration
Participation is open to researchers, clinicians, and students interested in tumour immunology. We look forward to engaging discussions shaping the future of cancer immunology.
Full program:
September 10, 2026:
Daniel Peeper (Nederlands Kanker Instituut) – Translating the cancer-immune dialogue
October 8, 2026:
Jurgen Kuball (UMC Utrecht) – From Bench to Bedside: Academic Valorization in Practice, Lessons from the TEG concept
November 12, 2026:
Anne Rios (Prinses Máxima Centerum) – Visualize cancer immunotherapy innovation
December 10, 2026:
Iosifina Foskolou (Sanquin) – Hypoxia as an architect of T cell immunity
January 14, 2027:
Fabio Marino (Utrecht University) – From antigen discovery to clinical impact: integrating technology and immuno-biology
February 11, 2027:
Kelly Stecker (Utrecht University) – Decoding immune cell-tumor communication with proteomics
March 11, 2027:
Sabrina Oliveira (Utrecht University) – Nanobodies in targeted cancer therapies
Venue: David de Wied Building M2.01
April 8, 2027:
Stefan Nierkens (Prises Máxima Centrum / UMC Utrecht) – Being a bloody good host for cell therapy
May 13, 2027:
Judith Wienke (Prinses Máxima Centrum) – From TME to (CAR-)T: boost cellular immunotherapies for pediatric patients with solid tumors
June 10, 2027:
Zsolt Sebestyén (UMC Utrecht) – Can T cells get there? Understanding the barriers and drivers of effective anti-tumor immunity